High-Fat Lipid Emulsion Stability via Composite Emulsifiers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing enteral nutrition lipid emulsions with high fat content face stability issues such as fat separation and creaming during storage, leading to potential blockages in feeding tubes and instability, which complicates providing concentrated and shelf-stable nutritional solutions, especially for preterm infants.
Innovation Solution
Development of aqueous lipid emulsions with at least 33% lipids and citric acid esters of mono-and di-glycerides as emulsifiers, maintaining a pH of 6 to 7.2 and ensuring minimal particle size variation over time, resulting in shelf-stable products for up to 12 months without significant fat coalescence or osmolality issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high fat content (at least 33% lipids) is used in enteral nutrition lipid emulsions, then caloric intake is maximized, but stability deteriorates with fat separation and creaming during storage
Solution Approach 1:
The patent changes the pH parameter to a neutral range (6.0-7.2) and controls osmolality (200-400 mOsm/kg) to stabilize the high-fat emulsion. This parameter optimization prevents fat separation and creaming while maintaining at least 33% lipid content, resolving the contradiction between high caloric density and storage stability
Solution Approach 2:
The patent uses composite emulsifier systems combining phospholipids (0.5-2.0%), citric acid esters of mono- and di-glycerides (0.1-1.0%), and protein hydrolysates (0.1-1.0%). This multi-component emulsifier composite provides synergistic stabilization of the high-fat emulsion, preventing phase separation while maintaining nutritional concentration
2Quantity of substance
If high concentration of lipids is formulated, then caloric density is improved, but manufacturing complexity increases due to stability control requirements
Solution Approach 1:
The patent establishes specific parameter ranges (pH 6.0-7.2, osmolality 200-400 mOsm/kg, water content 30-65%) that simplify the formulation process. By targeting these predefined parameters, manufacturers can achieve stable high-caloric emulsions without excessive complexity in formulation development and quality control
3Duration of action of stationary object
If shelf life is extended (up to 12 months), then product availability is improved, but stability maintenance becomes more difficult
Solution Approach 1:
The patent employs a composite emulsifier system with phospholipids, citric acid esters, and protein hydrolysates that work synergistically to maintain particle size stability over extended storage. This multi-component approach creates a robust protective barrier around lipid droplets, preventing coalescence and maintaining emulsion integrity for up to 12 months
Solution Approach 2:
The patent optimizes pH (6.0-7.2) and osmolality (200-400 mOsm/kg) parameters to create a stable environment that prevents lipid separation during long-term storage. These parameter controls, combined with the composite emulsifier system, enable shelf life extension to 12 months while maintaining particle size uniformity and preventing creaming
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aqueous lipid emulsions remain stable with minimal particle size change and uniform zeta potential, ensuring prolonged shelf life and effective enteral nutrition delivery, reducing the risk of feeding tube blockages and supporting the nutritional needs of preterm infants with sustained DHA and ARA levels.
Implementation Method 1
The aqueous lipid emulsion may comprise at least one emulsifier consisting of citric acid esters of mono- and di-glycerides
Implementation Method 2
The lipids may comprise at least one emulsifier consisting of citric acid esters of mono- and di-glycerides
Data Source
AI summary
Aqueous lipid emulsions for providing enteral nutrition are provided. The aqueous lipid emulsions include at least 33% of lipids, lipid soluble nutrients, or a combination thereof, based upon the total weight of the emulsion, and are essentially free of carbohydrate and protein. The aqueous lipid emulsions are shelf-stable for at least 7 months. The aqueous lipid emulsions are a source of supplemental enteral nutrition for any patient in need thereof, including preterm infants.